MORGAN GALLIART: Open Payments
NPI 1427533967 · RUSSELL, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$391 in 23 payments from 10 companies in 2025. Trend: 2023 $359 · 2024 $362 · 2025 $391
Food & beverage: $391
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 4 | $60 |
| Amgen Inc. | 3 | $50 |
| Insulet Corporation | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| ABBVIE INC. | 3 | $47 |
| Electromed, Inc. | 3 | $42 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $2 |
Products named: LEQVIO, EVENITY, Omnipod, GEMTESA, FARXIGA, SMARTVEST, ELIQUIS, UBRELVY.
Industry payments across KS — which companies pay providers there.
